Anti-CD137 mAb treatment inhibits experimental autoimmune uveitis by limiting expansion and increasing apoptotic death of uveitogenic T cells

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 2, 2005, Pages 596-603

  Shao, Hui ^a   Fu, Yangxin ^b   Liao, Tianjiang ^a   Peng, Young ^a   Chen, Lieping ^c   Kaplan, Henry J ^a   Sun, Deming ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE UVEITIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UVEITIS;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD137; APOPTOSIS; AUTOIMMUNE DISEASES; CELL PROLIFERATION; EYE PROTEINS; FEMALE; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MICE; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; RETINOL-BINDING PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; UVEITIS, POSTERIOR;

EID: 13944278756     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-0835     Document Type: Article

References (50)

1. Wacker WB, Donoso LA, Kalsow CM, Yankeelov JA Jr, Organisciak DT. Experimental allergic uveitis: isolation, characterization, and localization of a soluble uveitopathogenic antigen from bovine retina. J Immunol. 1977;119:1949-1958.
2. Gery I, Wiggert B, Redmond TM, et al. Uveoretinitis and pinealitis induced by immunization with interphotoreceptor retinoid-binding protein. Invest Ophthalmol Vis Sci. 1986;27:1296-1300.
3. Donoso LA, Menyman CF, Sery T, Sanders R, Vrabec T, Fong SL. Human interstitial retinoid binding protein: A potent uveitopathogenic agent for the induction of experimental autoimmune uveitis. J Immunol. 1989;143:79-83.
4. Broekhuyse RM, Kuhlmann ED, Winkens HJ. Experimental autoimmune anterior uveitis (EAAU). II. Dose-dependent induction and adoptive transfer using a melanin-bound antigen of the retinal pigment epithelium. Exp Eye Res. 1992;55:401-411.
5. Bora NS, Kim MC, Kabeer NH, et al. Experimental autoimmune anterior uveitis: induction with melanin-associated antigen from the iris and ciliary body. Invest Ophthalmol Vis Sci. 1995;36: 1056-1066.
6. Constantinescu CS, Lavi E. Anterior uveitis in murine relapsing experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). Curr Eye Res. 2000;20:71-76.
7. Bullington SJ, Waksman BH. Uveitis in rabbits with experimental allergic encephalomyelitis. Arch Ophthalmol. 1958;59:435-445.
8. Shao H, Sun SL, Kaplan HJ, Sun D. Induction of autoimmune encephalomyelitis and uveitis in B6 and (BoxSJL) mice by peptides derived from myelin/oligodendrocyte glycoprotein. J Neuroimmunol. 2002;132:117-122.
9. Hu LH, Redmond TM, Sanui H, et al. Rat T-cell lines specific to a nonimmunodominant determinant of a retinal protein (IRBP) produce uveoretinitis and pinealitis. Cell Immunol. 1989;122:251-261.
10. Agarwal RK, Rang Y, Zambidis E, Scott DW, Chan CC, Caspi RR. Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest. 2000;106:245-252.
11. Shao H, Song L, Sun SL, Kaplan HJ, Sun D. Conversion of monophasic to recurrent autoimmune disease by autoreactive T cell subsets. J Immunol. 2003;171:5624-5630.
12. Shao H, Lei S, Sun S, Xiang J, Kaplan HJ, Sun D. CpG-ODN1826 converts the weak uveitogenic rat IRBP1181-91 peptide into a strong uveitogen. J Immunol. 2003;171:4780-4785.
13. Salomon B, Bluestone JA. Complexities of cd28/b7: ctla-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19:225-252.
14. Vanderlugt CL, Karandikar NJ, Lenschow DJ, Dalcanto MC, Bluestone JA. Treatment with intact anti-B7-1 MAb during disease remission enhances epitope spreading and exacerbates relapses in R-EAE. J Neuroimmunol. 1997;79:113-118.
15. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med. 1995;181:1145-1155.
16. DeBenedette MA, Shahinian A, Mak TW, Watts TH. Costimulation of CD28-T lymphocytes by 4-1BB ligand. J Immunol. 1997;158: 551-559.
17. Chu NR, DeBenedette MA, Stiernholm BJ, Barber BH, Watts TH. Role of IL-12 and 4-1BB Iigand in cytokine production by CD28+ and CD28-T cells. J Immunol. 1997;158:3081-3089.
18. Saoulli K, Lee SY, Cannons JL, et al. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med. 1998;187:1849-1862.
19. Vinay DS, Kwon BS. Role of 4-1BB in immune responses. SeminImmunol. 1998;10:481-489.
20. Pollok KE, Kirn YJ, Zhou, Z, et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol. 1993;150:771-781.
21. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol. 1998;190:167-172.
22. Goodwin RG, Alderson MR, Smith CA, et al. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell. 1993;73: 447-456.
23. Alderson MR, Smith CA, Tough TW, et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol. 1994;24:2219-2227.
24. DeBenedette MA, Chu NR, Pollok KE, et al. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J Exp Med. 1995;181:985-992.
25. Salih HR, Kosowski SG, Haluska VF, et al. Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J Immunol. 2000;165:2903-2910.
26. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 1997;186:47-55.
27. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3:682-685.
28. Blazar BR, Kwon BS, Panoskaltsis-Mortari A, et al. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol. 2001;166:3174-3183.
29. DeBenedette MA, Wen T, Bachmann MF, et al. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol. 1999;163:4833-4841.
30. Sun Y, Lin X, Chen HM, et al. X. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol. 2002;168: 1457-1465.
31. Sun Y, Chen HM, Subudhi SK, et al. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med. 2002;8:1405-1413.
32. Foell J, McCausland M, Burch J, et al. CD137-mediated T cell co-stimulation terminates existing autoimmune disease in SLE-prone NZB/NZW F1 mice. Ann NY Acad Sci. 2003;987:230-235.
33. Foell J, Strahotin S, O'Neil SP et al. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest. 2003;111:1505-1518.
34. Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol. 1999;162:5037-5040.
35. Kim J, Choi SP, La S, et al. Constitutive expression of 4-1BB on T cells enhances CD4+ T cell responses. Exp Mol Med. 2003;35: 509-517.
36. Wilcox RA, Flies DB, Zhu G, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest. 2002;109:651-659.
37. Shao H, Fu YX, Song L, Sun S, Kaplan HJ, Sun D. LTßR-Ig treatment blocks actively induced, but not adoptively transferred, uveitis in Lewis rats. Eur J Immunol. 2003;33:1736-1743.
38. Thurau SR, Chan CC, Nussenblatt RB, Caspi RR. Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals. Clin Exp Immunol. 1997;109:370-376.
39. Chan CC, Caspi RR, Ni M, et al. Pathology of experimental autoimmune uveoretinitis in mice. J Autoimmun. 1990;3:247-255.
40. Chalupny NJ, Peach R, Hollenbaugh D, Ledbetter JA, Farr AG, Aruffo A. T-cell activation molecule 4-1BB binds to extracellular matrix proteins. Proc Natl Acad Sci USA. 1992;89:10360-10364.
41. Shao H, Woon, MD, Nakamura S, et al. Requirement of B7-mediated costimulation in the induction of experimental autoimmune anterior uveitis. Invest Opbthalmol Vis Sci. 2001;42:2016-2021.
42. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992;71:1065-1068.
43. Bluestone JA. New perspectives of CD28-B7-mediated T cell Co-stimulation. Immunity. 1995;2:555-559.
44. Gramaglia I, Cooper D, Miner KT, Kwon BS, Croft M. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand. Eur J Immunol. 2000;30:392-402.
45. Futagawa T, Akiba H, Kodama T, et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol. 2002;14:275-286.
46. Wilcox RA, Chapoval AI, Gorski KS, et al. Cutting edge: expression of functional CD137 receptor by dendritic cells. J Immunol. 2002; 168:4262-4267.
47. Michel J, Pauly S, Langstein J, Krammer PH, Schwarz H. CD137-induced apoptosis is independent of CD95. Immunology. 1999; 98:42-46.
48. Halstead ES, Mueller YM, Altman JD, Katsikis PD. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat Immunol. 2002;3:536-541.
49. Cannons JL, Lau P, Ghumman B, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol. 2001;167:1313-1324.
50. Morris GP, Chen L, Kong YC. CD137 signaling interferes with activation and function of CD4+CD25+ regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. Cell Immunol. 2003;226:20-29.